Physician-pharmaceutical industry interactions continue to generate heated debate in academic and public domains, both in the United States and abroad. Despite this, recent research suggests that physicians and physicians-in-training remain ignorant of the core issues and are ill-prepared to understand pharmaceutical industry promotion. Furthermore, few medical curricula cover this issue, despite warnings of the imperative need to address this gap in the education of tomorrow's physicians. There is a vast medical literature on this topic, but no single, concise resource. This book aims to fill that gap by providing a resource that explains the essential elements of this subject. The text makes the reader more aware of the key ethical issues and allows the reader to be a more savvy interpreter of industry promotion, have a heightened awareness of the public and medical legal consequences of some physician-pharmaceutical industry interactions and be better equipped to handle real-life encounters with industry.
Interactions
Physician-pharmaceutical industry interactions continue to generate heated debate in academic and public domains, both in the United States and abroad. Despite this, recent research suggests that physicians and physicians-in-training remain ignorant of the core issues and are ill-prepared to understand pharmaceutical industry promotion. Furthermore, few medical curricula cover this issue, despite warnings of the imperative need to address this gap in the education of tomorrow's physicians. There is a vast medical literature on this topic, but no single, concise resource. This book aims to fill that gap by providing a resource that explains the essential elements of this subject. The text makes the reader more aware of the key ethical issues and allows the reader to be a more savvy interpreter of industry promotion, have a heightened awareness of the public and medical legal consequences of some physician-pharmaceutical industry interactions and be better equipped to handle real-life encounters with industry. Understanding Physician-Pharmaceutical Industry Interactions is a long-overdue book summarizing deliberations that have spanned many years. I am a PGY (postgraduate year) 51; Dr. Shaili Jain is a PGY 8. Although two generations apart, we are in complete agreement with the need for coalesced thinking about the conflicts of self-interest in the relationship between the pharmaceutical industry and the profession of medicine. Dr. Jain is to be complimented for undertaking this subject that has undoubtedly caused her consternation as a young physician. This topic is very important for all health professionals who prescribe medicines or medical devices. Health care now consumes $2 trillion annually and is approaching 17% of the gross national product. And, as the costs continue to escalate, individuals, families, industry, and businesses and municipal, county, state and federal governments falter economically. Prescribing medical professionals, who are responsible for at least 75% of the annual cost of health care, unfortunately are often unaware of the cost of the drugs, tests, services and supplies they prescribe. The patients, except for their co-payments, are uninterested because of the confusion and complexities of billing, and, after all, a third party is responsible for Business ethics are different from medical ethics. In the business climate it is common for industry to reward and entice their vendors in order to stimulate sales. The pharmaceutical industry has a similar culture, and at its interface and overlap with the medical profession, what the pharmaceutical industry formally considers normal business behavior, the medical profession considers unethical. It is estimated that the pharmaceutical industry spends $14 billion per annum in marketing. According to statistics, there is one pharmaceutical representative for every nine physicians. It is a huge force. This, coupled with direct-to-consumer advertising, in which the bottom line is always "ask your doctor if this medicine is good for you," places the prescriber under increasing pressure. Medical ethics prompt physicians to consider that if current promotional activities such as inviting physicians to expensive dinners, parties, trips, entertainment and even office lunches as well as direct-to-consumer advertising were eliminated, the money saved could be used to lower the cost of drugs to the benefit of our patients. Understanding Physician-Pharmaceutical Industry Interactions outlines current thinking and guidelines for accomplishing that goal.
When I studied pharmacology in medical school, it was stressed that physicians should familiarize themselves with selected drugs, learn to understand them well and prescribe as few medicines as expeditiously as possible. Based on experience, we were taught to continue to use those medicines that were therapeutically effective, had a wide margin of safety and were least expensive among their class. These principles hold true today.
The American Medical Association was founded in 1847 for the purpose of developing a code of medical ethics to promote professionalism. As the addresses by this master mind of modern medicine are read, may you catch his vision of the almost boundless possibilities of your profession.
May you share with him his "relish of knowledge" and his absorbing love and passionate search for truth.
Above all, may there come to you an inspiration which will enable you to live a rich, a happy and an abundant life.
Sincerely yours, Eli Lilly and Company Eli Lilly President
I consider a gift of this nature to be a thoughtful expression. It is an inexpensive gift, but a valuable and useful reference for a physician's lifetime and beyond. The achievements in medicine during the 20th century were spectacular. Life expectancy in the United States has nearly doubled in 100 years. In the past 50 years, we have seen the conquest of poliomyelitis and the transplantation of organs, among so many other achievements. Society benefits from brilliant minds in basic science, medicine and pharmacology working collaboratively. It is In order to continue to advance along the road of discovery, the pharmaceutical industry and the medical profession must work in synergy. The relationship must be completely devoid of conflict of self-interest and greed. And the relationship between the prescriber of medicines and the pharmaceutical manufacturers (and their representatives) must not be self-serving for either. It is all about the patient and the betterment of society.
I think every young physician should have the opportunity to tour a pharmaceutical manufacturing company and marvel at and better appreciate the elaborateness and complexities of the drug production process. Bridging the chasm within the framework of science, ethics, service and professionalism will encourage mutual appreciation and respect.
This book, written by a young psychiatrist, brings it all into focus. It should serve to strengthen the importance of collaboration within the boundaries of ethics and professionalism. Upholding ethics and professionalism will, and should, solidify the matrix of the healing occupations.
Introduction
Why Write a Book about PhysicianPharmaceutical Industry Interactions (PPIIs)? 1 These interactions have consequences for patients, doctors and the larger society [1] . These interactions are frequent and involve more than just a face-to-face visit with a pharmaceutical company representative (PCR). Moynihan referred to these interactions as "entanglements," and examples are listed in Figure 0. 1. The budgets of the pharmaceutical industry (PI) 2 support many of the PPIIs, such as paying PCR salaries, providing free gifts for physicians and subsidizing funding for continuing medical education (CME). The marketing expenditure of the U.S. drug industry reached $15.7 billion in 2000 [2] with nearly one PCR and almost $100,000 for every eleven practicing physicians in the United States [3] . With the number of new medications coming onto the market only increasing, physicians are finding it hard to keep up to date, and many find that utilizing Introduction industry-supplied sources of information can be a convenient and easy way of staying current in their daily practice. As government funds diminish in academic settings and industry investment increases, this subject is likely to remain an important issue for the medical profession to study and understand [2] .
Who Should Read This Book?
This book should be read by any physician or medical trainee who has engaged in any of the interactions outlined in Figure 0 .1, as well
Forms of Entanglement
Ⅺ Face-to-face visits from drug company representatives Ⅺ Acceptance of direct gifts of equipment, travel or accommodation Ⅺ Acceptance of indirect gifts, through sponsorship of software or travel Ⅺ Attendance at sponsored dinners and social or recreational events Ⅺ Attendance at sponsored educational events, continuing medical education, workshops or seminars Ⅺ Attendance at sponsored scientific conferences Ⅺ Ownership of stock or equity holdings Ⅺ Conducting sponsored research Ⅺ Company funding for medical schools, academic chairs, or lecture halls Ⅺ Membership in sponsored professional societies and associations Ⅺ Advising a sponsored disease foundation or patients' group Ⅺ Involvement with or use of sponsored clinical guidelines Ⅺ Undertaking paid consultancy work for companies Ⅺ Membership of company advisory boards of "thought leaders" or "speakers' bureaus" Ⅺ Authoring "ghostwritten" scientific articles Ⅺ Reading medical journals that rely on drug company advertising, company-purchased reprints and sponsored supplements 
